Company: PRME
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023486
Chunk: 28

Company: Prime Medicine, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
Changes in operating assets and liabilities:Collaboration receivable — related party(17)— Prepaid expenses and other current assets(789)(2,794)Accounts payable1,884 (5,880)Accrued expenses and other current liabilities(6,655)(4,475)Accrued settlement payment — related party— (13,500)Deferred revenue — related party(1,438)— Lease liabilities(638)(3,462)Net cash used in operating activities(48,857)(67,707)Cash flows used in investing activities:Maturities of investments3,000 72,500 Purchases of investments(48,320)(107,208)Purchases of property and equipment(2,422)(2,324)Net cash used in investing activities(47,742)(37,032)Cash flows provided by financing activities:Proceeds from research and development funding liability6,000 6,000 Proceeds from follow-on offering, net of issuance costs— 132,055 Proceeds from issuance of pre-funded warrants, net of issuance costs— 18,800 Proceeds from ESPP offerings— 436 Net proceeds from stock option exercises— 36 Net cash provided by financing activities6,000 157,327 Net change in cash, cash equivalents, and restricted cash(90,599)52,588 Cash, cash equivalents, and restricted cash at beginning of period196,538 55,070 Cash, cash equivalents, and restricted cash at end of period$105,939 $107,658 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

9

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three Months EndedMarch 31,(in thousands)20252024Reconciliation of cash, cash equivalents and restricted cash:Cash, cash equivalents, and restricted cash at end of period$105,939 $107,658 Less: restricted cash14,062 13,496 Total cash, and cash equivalents$91,877 $94,162 Supplemental cash flow information:Right-of-use assets obtained in exchange for new operating lease liabilities$83,757 $44,935 Decrease in right-of-use assets due to lease termination$3,120 $— Supplemental disclosure of non-cash investing and financing activities:Purchases